EVRALENT Trademark

Trademark Overview


On Thursday, May 16, 2019, a trademark application was filed for EVRALENT with the United States Patent and Trademark Office. The USPTO has given the EVRALENT trademark a serial number of 79263054. The federal status of this trademark filing is REGISTERED as of Tuesday, February 4, 2020. This trademark is owned by Glaxo Group Limited. The EVRALENT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
evralent

General Information


Serial Number79263054
Word MarkEVRALENT
Filing DateThursday, May 16, 2019
Status700 - REGISTERED
Status DateTuesday, February 4, 2020
Registration Number5974602
Registration DateTuesday, February 4, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 19, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Friday, July 28, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, June 5, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, May 15, 2020FINAL DISPOSITION NOTICE SENT TO IB
Friday, May 15, 2020FINAL DISPOSITION PROCESSED
Monday, May 4, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, February 4, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, November 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2019PUBLISHED FOR OPPOSITION
Saturday, November 16, 2019NOTIFICATION PROCESSED BY IB
Wednesday, October 30, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 30, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 10, 2019ASSIGNED TO LIE
Tuesday, October 8, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 4, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 2, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 2, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 13, 2019REFUSAL PROCESSED BY IB
Tuesday, August 27, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, August 27, 2019REFUSAL PROCESSED BY MPU
Saturday, August 3, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, August 2, 2019NON-FINAL ACTION WRITTEN
Thursday, August 1, 2019ASSIGNED TO EXAMINER
Tuesday, July 23, 2019APPLICATION FILING RECEIPT MAILED
Friday, July 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 18, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB